271 related articles for article (PubMed ID: 30207284)
1. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
2. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
4. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
5. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.
Yu D; Shi J; Sun T; Du X; Liu L; Zhang X; Lu C; Tang X; Li M; Xiao L; Zhang Z; Yuan Q; Yang M
Tumour Biol; 2012 Jun; 33(3):877-84. PubMed ID: 22249976
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Marabese M; Ganzinelli M; Garassino MC; Shepherd FA; Piva S; Caiola E; Macerelli M; Bettini A; Lauricella C; Floriani I; Farina G; Longo F; Bonomi L; Fabbri MA; Veronese S; Marsoni S; Broggini M; Rulli E
Oncotarget; 2015 Oct; 6(32):34014-22. PubMed ID: 26416458
[TBL] [Abstract][Full Text] [Related]
8. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
11. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
[TBL] [Abstract][Full Text] [Related]
13. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Cuffe S; Azad AK; Qiu X; Qiu X; Brhane Y; Kuang Q; Marsh S; Savas S; Chen Z; Cheng D; Leighl NB; Goss G; Laurie SA; Seymour L; Bradbury PA; Shepherd FA; Tsao MS; Chen BE; Xu W; Liu G
Cancer Epidemiol; 2016 Apr; 41():50-6. PubMed ID: 26816351
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Chen R; Fen Y; Lin X; Ma T; Cai H; Ding H
Technol Cancer Res Treat; 2016 Dec; 15(6):815-820. PubMed ID: 26376695
[TBL] [Abstract][Full Text] [Related]
15. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.
Shukuya T; Ko R; Mori K; Kato M; Yagishita S; Kanemaru R; Honma Y; Shibayama R; Koyama R; Shimada N; Takahashi K
Cancer Chemother Pharmacol; 2015 Oct; 76(4):771-6. PubMed ID: 26259641
[TBL] [Abstract][Full Text] [Related]
18. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
[TBL] [Abstract][Full Text] [Related]
19. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
[TBL] [Abstract][Full Text] [Related]
20. The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy.
Zhou F; Gao G; Ren S; Li X; He Y; Zhou C
PLoS One; 2013; 8(4):e61585. PubMed ID: 23620771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]